trending Market Intelligence /marketintelligence/en/news-insights/trending/VYRahSWW1fNOCVNBI3SAfg2 content esgSubNav
In This List

Johnson & Johnson to expand coverage of joints drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Johnson & Johnson to expand coverage of joints drug

Janssen Biotech Inc. sought U.S. FDA approval to expand Simponi Aria's coverage as a treatment for active psoriatic arthritis and active ankylosing spondylitis.

The Johnson & Johnson unit filed two supplemental biologics license applications for the drug, which is already approved as a therapy for adult patients with moderate to severe active rheumatoid arthritis.

Psoriatic arthritis and ankylosing spondylitis affect more than 2 million Americans, Johnson & Johnson noted in a news release.

Arthritis is any disorder that affects joints. Ankylosing spondylitis is a form of arthritis.